Tuesday, 29 June 2021

15:40-16:00 Opening
- Welcome
- Introduction EBMT and COVID19 pandemic
  Rafael de la Cámara (Spain)
  Nicolaus Kröger (Germany)

16:00-17:35 The virus
- Chair: D. Navarro
- Mutations, variants and strains. What do they mean? How do they emerge? What is the situation of the new strains? What implications they have?
  Fernando González Candelas (Spain)
- Diagnostic Toolbox for SARS-CoV-2: What Works When and Why?
  Hans Hirsch (Switzerland)
- Prolonged PCR positivity in HSCT and oncohematologic patients. How frequent is it? What means?
  Fausto Baldanti (Italy)
- Update on SARS-COV-2 transmission mechanisms
  Lidia Morawska (Australia)

17:35-17:45 Break

17:45-18:15 Quality in HSCT
- Chairs: N. Worel & J. Snowden
- Maintaining quality standards during the COVID-19 pandemic
  John Snowden (UK) & Sarah Holtby (UK)
- Live Q&A

18:15-18:25 Break

18:25-19:50 Donor’s standards
- Chairs: N. Worel & J. Snowden
- Do we have to test donors for SARS-CoV-2? When and how?
  Rafael de la Cámara (Spain)
- Impact of cryopreservation in HSCT outcome
  Boris Calmels (France)
- Related donors
  Nina Worel (Austria)
- Unrelated Donors
  Hung Yang (Australia)
- Live Q&A
Wednesday, 30 June 2021

15:45-17:00  
**Clinical Impact and management in HSCT patient 1**  
*Chairs: P. Ljungman & M. Mikulska*

*Activity impact and clinical outcome*

- EBMT experience
- USA experience: COVID19: Clinical Experience at Memorial Sloan Kettering Cancer Center
- Asian Pacific BM Society experience (APBMT)
- Live Q&A

Per Ljungman (Sweden)  
Genovefa Papanicolau (USA)  
William YK Hwang (Singapore)

17:00-17:10  
Break

17:10-18:00  
**Clinical Impact and management in HSCT patient 2**  
*Chairs: P. Ljungman & M. Mikulska*

- Other/organ complications
- Measures to limit SARS-COV-2 nosocomial outbreaks in transplant units
- Live Q&A

Akshay Sharma (USA)  
Roy Chemaly (USA)

18:00-18:15  
Break

18:15-19:30  
**Clinical Impact and management in HSCT patient 3**  
*Chairs: J. Styczynski & R. de la Cámara*

- COVID-19 in HSCT paediatric patients. *It is really a low frequency and benign disease?*
- Epidemiology of other common seasonal respiratory viruses in HSCT during SARS-COV-2 pandemic
- Fungal and bacterial superinfections in COVID patients
- Live Q&A

Dina Averbuch (Israel)  
José Luís Piñana (Spain)  
Carolina Garcia-Vidal (Spain)

19:30-19:40  
Break

19:40-20:30  
**Clinical Impact and management in HSCT patient 4**  
*Chairs: J. Styczynski & R. de la Cámara*

*Updated in COVID-19 therapy*

- Antivirals, convalescent plasma, immunomodulation
- Oxygen support, Ventilation, anticoagulation
- Live Q&A

Malgorzata Mikulska (Italy)  
Ellie Azoulay (France)
Thursday, 1 July 2021

15:00-15:45  Industry Symposium kindly sponsored by Jazz Pharmaceuticals

15:45-16:50 Nursing and patients’ perspective
- Nursing HSCT in COVID pandemic
- PPE and the difficulties of isolation/protective environment
- Patients’ perspective
- Live Q&A

Chair: J. Murray
Michelle Kenyon (UK)
Iris Agreiter (Ireland)
Natacha Bolaños (Spain)

16:50-17:10 Break

17:10-18:30 Immune response and prevention 1
How is the immune response to SARS-CoV-2?
- General aspects
  How to measure T and B cell response against SARS-CoV-2.
  Duration of the immune response
  Protective immunity: can we define it?
- Antibody and B cell responses to COVID-19 disease and vaccination
- Specific aspects of immune response to SARS-CoV-2 in HSCT
- Live Q&A

Chairs: C. Cordonnier & D. Averbuch
Hans-Gustaf Ljunggren (Sweden)
Karin Loré (Sweden)
Michael Boeck (US)

18:30-18:40 Break

18:40-19:10 Immune response and prevention 2
Vaccines
- Type of vaccines
- Experiences in immunosuppressed /HSCT patients
- Recommendations
- Live Q&A

Chair: D. Averbuch
Catherine Cordonnier (France)

19:10-19:15 Closing Remarks
Nicolaus Kröger